There are 2934 resources available
5387 - Health-related quality of life (HRQL) in a randomized phase 3 trial of enzalutamide with standard first line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial
Presenter: Martin Stockler
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
3307 - Switch Maintenance Gemcitabine After First Line Chemotherapy In Patients With Malignant Mesothelioma; A Multicenter Open Label Phase II Trial (NVALT19)
Presenter: Sjaak Burgers
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies - Invited Discussant 1740PD, 1741PD, 1742PD and LBA92
Presenter: Giuseppe Lo Russo
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Presentation by expert
Presenter: Maria De Santis
Session: Specificity of upper tract urothelial carcinoma biology and management
Resources:
Slides
2754 - Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses
Presenter: Wassim Abida
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
3623 - Phase II Study of Pembrolizumab with Enzalutamide (Enz) in Metastatic, Castration Resistant Prostate Cancer (mCRPC): 30 patient expansion with examination of tumor infiltrating immune cells and fecal microbiota
Presenter: Julie Graff
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1823 - Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
2495 - Docetaxel for hormone-naïve prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial (NCT00268476)
Presenter: Nicholas James
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1199 - Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1_RT comparison”
Presenter: Syed Adnan Ali
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1910 - Patient-Reported Outcomes (PROs) From TITAN: a Phase 3, Randomized, Double-Blind Study of Apalutamide (APA) Versus Placebo (PBO) Added to Androgen Deprivation Therapy (ADT) in Patients (pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Presenter: Neeraj Agarwal
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract